Johnson & Johnson
About Johnson & Johnson’s 13F portfolio
Johnson & Johnson is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Johnson & Johnson reported $798.7M across 15 US-listed positions (). Its largest position is PROTAGONIST THERAPEUTICS INC (PTGX) at 38% of the reported book, and its ten biggest holdings make up 98% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: PTGX PROTAGONIST THERAPEUTICS INC | $127.16 +2.00% | 38% | 2.4M | $300.2M |
| 2 | NASDAQ: NBTX NANOBIOTIX | $26.90 −2.00% | 27% | 5.6M | $212.0M |
| 3 | NASDAQ: MGTX MEIRAGTX HLDGS PLC | $8.32 −1.65% | 11% | 6.6M | $89.7M |
| 4 | NASDAQ: RAPP RAPPORT THERAPEUTICS INC | $23.40 −1.52% | 9.3% | 1.8M | $74.4M |
| 5 | NASDAQ: CTNM CONTINEUM THERAPEUTICS INC | $9.24 −3.25% | 4.1% | 2.0M | $32.4M |
| 6 | NASDAQ: LEGN LEGEND BIOTECH CORP | $16.25 +0.87% | 2.9% | 815K | $23.5M |
| 7 | NASDAQ: CVRX CVRX INC | $0.60 −1.15% | 2.6% | 4.0M | $20.7M |
| 8 | NASDAQ: XNCR XENCOR INC | $34.39 −0.32% | 1.5% | 748K | $12.0M |
| 9 | TSX: CBRS CEREBRAS SYSTEMS INC | — — | 1.5% | 54K | $11.8M |
| 10 | NASDAQ: FATE FATE THERAPEUTICS INC | $1.05 +2.94% | 1.1% | 3.4M | $9.1M |
| 11 | NASDAQ: PRCT PROCEPT BIOROBOTICS CORP | $25.18 +5.89% | 1.0% | 358K | $8.1M |
| 12 | NASDAQ: NMRA NEUMORA THERAPEUTICS INC. | $0.37 +9.66% | 0.4% | 1.8M | $3.1M |
| 13 | NASDAQ: VOR VOR BIOPHARMA INC | $17.83 −1.93% | 0.1% | 54K | $989K |
| 14 | NASDAQ: LAB STANDARD BIOTOOLS INC | $0.57 +5.67% | 0.0% | 312K | $257K |
| 15 | NASDAQ: ACET ADICET BIO INC | $2.50 −10.07% | 0.0% | 23K | $197K |
Showing the 15 largest positions reported in this 13F.
- Healthcare99%
- NewCBRSCEREBRAS SYSTEMS INC—$11.8M
- SoldNNOXNano-X Imaging Ltd.−100%—
- SoldRLYBRallybio Corporation−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | JNJ Johnson & Johnson | 13G | 7.5% | 180.6M | Filed 01 MAY 2026 |
Showing all 1 disclosed stakes.
Reading Johnson & Johnson’s 13F portfolio
Johnson & Johnson’s $798.7M 13F book is spread across 15 reported positions and is highly concentrated — its ten largest positions alone are 98% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are PTGX, NBTX, MGTX, RAPP and CTNM, led by PROTAGONIST THERAPEUTICS INC (PTGX) at 38% of the portfolio. The heaviest sector exposure is Healthcare (99%).
What Johnson & Johnson changed last quarter
Between 2026-03-31 and Q2 2026, Johnson & Johnson was a net seller: it opened 1 new positions and added to 0 more, while trimming 0 and closing 2 outright. Against a 15-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was CEREBRAS SYSTEMS INC (CBRS), and its biggest reduction was Nano-X Imaging Ltd. (NNOX).
What a 13F does and doesn’t reveal
A 13F captures only Johnson & Johnson’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Johnson & Johnson is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Johnson & Johnson's profile on this page is built directly from those filings.
How current is the 13F data on Johnson & Johnson's page?
It reflects Johnson & Johnson's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Johnson & Johnson files its next quarterly report, this page refreshes automatically.
Can I see Johnson & Johnson's complete list of holdings?
This page highlights Johnson & Johnson's largest positions rather than all 15 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Johnson & Johnson's filings.
Does a 13F show everything Johnson & Johnson owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Johnson & Johnson's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Johnson & Johnson made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

